Is Aspirin Bad for Your Liver?

At the doses most people take, aspirin poses very little threat to your liver. The kind of liver injury associated with aspirin is overwhelmingly linked to high therapeutic doses, the sort once prescribed for conditions like rheumatic fever and juvenile arthritis, not the low-dose tablet you might take for heart protection. That said, “very little threat” is not the same as “zero threat,” and a few groups of people face meaningfully higher risk. What makes the aspirin-liver story genuinely interesting is that the same drug suspected of causing liver harm in some circumstances appears to protect the liver in others.

How Common Is Aspirin-Related Liver Damage

Liver injury from any nonsteroidal anti-inflammatory drug, aspirin included, is rare. Across clinical studies, the rate of NSAID-induced liver disease ranges from roughly 0.3 to 9 per 100,000 patients, with liver-related hospitalizations somewhat higher at 3 to 23 per 100,000.¹ Those numbers span the entire NSAID class, and aspirin sits in the middle of the pack rather than at the top. Liver reactions to NSAIDs range from mild, silent bumps in liver enzymes that resolve on their own to, in very rare cases, outright liver failure. The practical takeaway is that if you are otherwise healthy and using aspirin at standard doses, liver injury is an unlikely event.

When liver injury does happen, the pattern tends to follow a predictable sequence. Enzyme levels rise, sometimes dramatically, within days to a couple of weeks after starting high-dose therapy. A prospective study of children on aspirin for juvenile rheumatoid arthritis found that three developed severe enzyme elevations within 5 to 14 days of starting treatment. Another 19 showed moderate changes. Importantly, liver tests returned to normal in many of those children even while they continued taking the drug, and in all of them once aspirin was stopped.² That reversibility is one reason aspirin-related liver damage rarely makes it into the headlines: the liver is remarkably good at recovering once the offending dose is removed.

What Happens Inside Liver Cells at High Doses

The way aspirin damages liver cells at high concentrations has been studied in detail using human liver cell lines. The core problem is oxidative stress. Aspirin ramps up the production of reactive oxygen species inside the cell while simultaneously draining the cell’s main antioxidant defense, a molecule called glutathione. When glutathione drops, the cell loses its ability to neutralize those damaging molecules, and the situation snowballs.³

The downstream damage centers on mitochondria, the structures that generate energy for the cell. Aspirin at toxic levels inhibits key enzymes in the mitochondrial energy chain, cutting ATP production and destabilizing the mitochondrial membrane. Once the membrane falters, the cell triggers its self-destruct program.⁴ In lab experiments, pretreating cells with N-acetylcysteine, a compound that replenishes glutathione, partially rescued them from aspirin’s effects, which reinforces the idea that the liver’s own antioxidant reserves are what stand between a therapeutic dose and a toxic one.⁵

These are cell-culture findings, so they describe what can happen under controlled laboratory conditions rather than what routinely happens in a living person. But they explain why high blood levels of salicylate (the active breakdown product of aspirin) are the consistent thread in clinical case reports of liver injury: once aspirin overwhelms the cell’s defenses, the damage mechanism kicks in quickly.

When Aspirin Causes Acute Liver Injury

Severe, acute liver injury from aspirin is rare enough to be published as individual case reports. One documented case involved a patient started on high-dose aspirin along with warfarin. Within 48 hours, her liver enzyme levels skyrocketed to more than 50 times normal, and her blood clotting became dangerously impaired. After aspirin and warfarin were stopped and she was treated with supportive care including N-acetylcysteine, her liver tests improved over the next three days.⁶ The temporal relationship between starting aspirin and the onset of symptoms, together with the rapid improvement after stopping the drug, pointed strongly to aspirin as the cause.

Cases like this almost always involve high doses, preexisting conditions, or combinations with other drugs that stress the liver. The patient in that case was also on warfarin, which is itself processed by the liver. When multiple liver-metabolized drugs compete for the same clearance pathways, the risk of toxicity goes up. Aspirin is broken down by several liver enzymes, and variations in the genes coding for those enzymes can affect how quickly or slowly you clear the drug.⁷ People who metabolize aspirin slowly may be more susceptible to toxicity at doses that are safe for others.

Who Faces Higher Risk

Several groups are known to be more vulnerable to aspirin-related liver problems, and understanding who they are matters more than blanket warnings about the drug.

Children with viral illness: Reye syndrome is the most famous link between aspirin and liver damage. It typically follows a viral infection, with a gap of a few days before symptoms appear. The underlying problem is a widespread breakdown in mitochondrial function, and aspirin is one of the exogenous agents implicated in triggering it.⁸ After the association was publicized in the early 1980s, aspirin use in children plummeted, and reported cases of Reye syndrome dropped from a peak of 555 in 1980 to no more than 36 per year after 1987.⁹ That dramatic decline is strong, if indirect, evidence that aspirin played a real role. The recommendation against giving aspirin to children and teenagers during febrile illness remains one of the clearest public health successes in drug safety.
People with autoimmune conditions: Patients with systemic lupus erythematosus have long been recognized as especially susceptible to aspirin-induced liver enzyme elevations. The reasons likely involve both the underlying inflammatory state of the liver in these patients and altered drug metabolism. Research in this area dates back decades.¹⁰
Patients already on multiple liver-processed drugs: As described in the acute injury case above, combining aspirin with other hepatically metabolized medications raises the stakes. This is not unique to aspirin; it is a general principle of pharmacology that multiple drugs competing for the same enzymes can push any one of them toward toxicity.
People with certain genetic variants: Genetic differences in enzymes like CYP2C9 and several others involved in NSAID metabolism have been linked to higher risk of liver injury from this drug class.¹⁰ You would not typically know your genotype for these enzymes, but a history of unusual reactions to NSAIDs is a practical signal worth mentioning to your doctor.

Aspirin and Existing Liver Disease

If you already have liver disease, the question shifts from “can aspirin hurt my liver” to “is it safe to use aspirin at all.” The answer is more reassuring than you might expect. A review of the evidence on anticoagulants and antiplatelet agents in patients with cirrhosis found that antiplatelet drugs, aspirin included, are generally safe to use, though they are mostly contraindicated in severe hepatic impairment. The main concern in advanced liver disease is not further liver damage from the drug itself but bleeding risk, since cirrhosis already disrupts the body’s clotting system. Severe thrombocytopenia, where platelet counts are very low, is a relative contraindication.¹¹

This is an area where clinical judgment matters far more than a general rule. Someone with mild, stable liver disease may tolerate low-dose aspirin without trouble. Someone with decompensated cirrhosis and low platelet counts is a very different story. The decision is made patient by patient, weighing cardiovascular benefit against bleeding risk.

Aspirin Compared to Acetaminophen

Many people conflate aspirin’s liver risk with that of acetaminophen (Tylenol), but the two drugs are fundamentally different in how they interact with the liver. Acetaminophen is the leading cause of acute liver failure from drug overdose in many countries, and it can cause liver toxicity even at normal doses in some people, particularly those who drink alcohol or are fasting. Aspirin, by contrast, is more associated with prolonged inhibition of blood clotting than with direct liver damage.¹² The mechanism of liver toxicity is also different: acetaminophen generates a directly toxic metabolite (NAPQI) that destroys liver cells when glutathione is depleted, while aspirin’s liver effects are driven by mitochondrial stress and oxidative damage at high concentrations, as described earlier. If you are worried about your liver specifically, aspirin is the less concerning of the two at over-the-counter doses.

The Protective Side of Aspirin

Here is where the story becomes genuinely counterintuitive. A growing body of research suggests that regular aspirin use may protect against several forms of chronic liver disease rather than cause them.

In animal models of fatty liver disease, aspirin reduced fat accumulation and inflammation in liver tissue by activating a metabolic pathway that promotes fat burning and suppresses fat production.¹³ Separately, aspirin has been shown to suppress the activation of hepatic stellate cells, the cells responsible for producing scar tissue in the liver. When these cells are quieted, inflammatory signaling drops and fibrosis slows.¹⁴ Liver fibrosis is the precursor to cirrhosis, so anything that slows it down is clinically meaningful.

The most striking findings involve liver cancer. A large Swedish study with a median follow-up of about eight years found that aspirin users had an estimated cumulative incidence of hepatocellular carcinoma of 4.0%, compared to 8.3% among non-users. After adjusting for other risk factors, aspirin use was associated with roughly a 31% lower risk of developing this cancer. The benefit appeared to grow with longer use: people who took aspirin for five or more years saw a roughly 43% lower adjusted risk compared to short-term users.¹⁵

Laboratory research has explored a possible mechanism: aspirin appears to inhibit platelet activity that otherwise promotes the growth and spread of liver cancer cells. Platelets do more than clot blood. They release growth factors and signaling molecules that cancer cells exploit. By dampening platelet activity, aspirin may cut off a supply line that tumors depend on.¹⁶

There is an important caveat. An updated meta-analysis found that the protective association between aspirin and liver cancer diminished to non-significance in the subgroup of patients who already had cirrhosis.¹⁷ This suggests that aspirin’s cancer-prevention benefit may apply most to people with chronic liver disease who have not yet progressed to cirrhosis. Once the liver is severely scarred, the protective window may have closed, and the bleeding risks of aspirin become more prominent.

The Dose Question

Almost everything about aspirin’s relationship with the liver comes back to dose. The high therapeutic doses once used for rheumatic diseases, sometimes reaching several grams per day, are where the toxicity signal lives. The low doses used for cardiovascular prevention, typically 75 to 100 milligrams daily, sit well below the threshold where liver stress typically appears.

One study examining different aspirin doses over 30 days found that all doses raised one liver enzyme marker (SGOT) after a month of treatment, but the effect was most pronounced at 75 mg enteric-coated and 100 mg doses, while higher doses of 150 mg and 300 mg paradoxically showed less significant changes. The same study found that most doses actually decreased another marker (SGPT), with the exception of the 75 mg enteric-coated formulation. The authors suggested that patients with existing liver insufficiency should avoid the 75 mg enteric-coated dose specifically.¹⁸ These somewhat surprising findings underscore that the dose-response relationship for aspirin and liver enzymes is not a simple straight line. Formulation, coating type, and individual patient factors all play a role.

For most healthy adults, the practical message is straightforward. A daily low-dose aspirin taken for a cardiovascular indication, under the guidance of a physician, is not meaningfully threatening to your liver. The situations that generate real concern involve high doses, concurrent use of other liver-stressing medications, preexisting liver vulnerability, or genetic quirks in how you metabolize the drug.

Reye Syndrome and How It Changed Aspirin’s Reputation

No discussion of aspirin and liver harm is complete without acknowledging Reye syndrome, even though its relevance today is mostly historical. In the late 1970s and early 1980s, clusters of children who had taken aspirin during viral illnesses like influenza or chickenpox developed a devastating syndrome: sudden vomiting, confusion, liver failure, and brain swelling. The liver pathology showed massive mitochondrial damage. Mortality rates in severe cases were alarmingly high.

The epidemiological link between aspirin and Reye syndrome was strong enough that the U.S. Surgeon General issued a warning in 1982, and aspirin labels were changed to warn against use in children with fever. The effect was swift. Reported cases in children peaked at 555 in 1980 and dropped to fewer than 36 per year by 1987.⁹ The biochemical explanation involves a generalized failure of mitochondrial metabolism triggered by the combination of viral infection and an exogenous agent like aspirin.⁸

Reye syndrome remains the primary reason aspirin carries a strong reputation as a liver toxin, even though the condition applies almost exclusively to children with active viral infections. Adults taking low-dose aspirin for heart disease are not at meaningful risk of Reye syndrome. But the legacy of those cases in the 1980s is powerful enough that many people assume aspirin is broadly dangerous to the liver when the real lesson was far more specific: do not give aspirin to children with fever.

When Genetics Complicate the Picture

Your genes influence how quickly you process aspirin and, by extension, how vulnerable you are to its toxic effects. Aspirin is metabolized by a handful of liver enzymes, and common genetic variants in the genes encoding these enzymes can alter the drug’s clearance rate.⁷ Slow metabolizers effectively build up higher blood levels of the drug’s active components at any given dose, which shifts the balance closer to the toxicity threshold described in the cell-culture studies.

Additional genetic risk factors specific to NSAID hepatotoxicity have been identified, including variants in other drug-metabolizing enzymes and in HLA alleles, which are genes involved in the immune system’s ability to distinguish self from foreign substances.¹⁰ This suggests that some cases of NSAID-related liver injury may involve an immune-mediated component, where the drug or its byproducts trigger an inappropriate immune attack on liver cells. Pharmacogenomic testing is not routine for aspirin prescriptions, but if you have a history of unusual liver enzyme elevations while taking any NSAID, a conversation with your doctor about genetic susceptibility is reasonable.

1
PubMed Central. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?
2
PubMed. Aspirin-induced hepatotoxicity in juvenile rheumatoid arthritis. A prospective study
3
PLOS ONE. Implications of Altered Glutathione Metabolism in Aspirin-Induced Oxidative Stress and Mitochondrial Dysfunction in HepG2 Cells
4
PubMed. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells
5
PLOS ONE. Potentiation of LPS-Induced Apoptotic Cell Death in Human Hepatoma HepG2 Cells by Aspirin via ROS and Mitochondrial Dysfunction: Protection by N-Acetyl Cysteine
6
PubMed Central. Aspirin-Induced Acute Liver Injury
7
PubMed Central. Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria
8
PubMed. Aspirin and Reye syndrome: a review of the evidence
9
PubMed. Reye’s syndrome in the United States from 1981 through 1997
10
PubMed. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity
11
PubMed. Review article: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis
12
PubMed. Aspirin and acetaminophen: should they be available over the counter?
13
PubMed Central. Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
14
PubMed Central. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-kB pathway
15
PubMed Central. Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
16
PubMed Central. Aspirin suppresses hepatocellular carcinoma progression by inhibiting platelet activity
17
PubMed Central. The Effect of Aspirin Use on Incident Hepatocellular Carcinoma—An Updated Systematic Review and Meta-Analysis
18
International Journal of Scientific Research in Knowledge. Aspirin Associated Liver Toxicity – The Optimal Dose of Aspirin in Liver Insufficiency